FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387424077> ?p ?o ?g. }

• W4387424077 abstract "Several recent studies have demonstrated that urinary levels of liver-type fatty acid-binding protein (L-FABP) can be used to stratify the prognosis of cardiac disease, cardiac intensive care unit admission, cirrhosis, and coronavirus disease 2019. Our initial prospective study revealed that urinary L-FABP (uL-FABP) was associated with a high probability of acute kidney injury after stem cell transplantation (SCT). However, the relevance of elevated uL-FABP to the prognosis of patients receiving SCT remains to be determined. We aimed to investigate whether uL-FABP levels can be used to stratify patient prognosis after SCT. To achieve this aim, we conducted a new long-term follow-up study using data from patients enrolled in our preceding prospective cohort study. Patients were classified into high and low uL-FABP groups based on levels measured at baseline (i.e., before initiating the conditioning regimen), using an uL-FABP cutoff of 8.4 μg/gCr, which was determined based on data from healthy adults. uL-FABP levels were also measured on days 0, 7, and 14 after SCT. Cox proportional hazard regression was used to examine the effects of each factor on survival outcomes, and Fine-Gray regression was used in the presence of competing risks. Multivariate analysis incorporating confounders was then performed for factors with P values <0.1 in the univariate analysis. In total, 20 of 84 patients (23.8%), 57 of 84 patients (67.9%), 34 of 49 patients (69.4%), and 34 of 46 patients (73.9%) were classified into the high uL-FABP group at baseline, on days 0, 7, and 14, respectively. The 5-year overall survival (OS) rates were 23.9% in the high uL-FABP group and 68.9% in the low uL-FABP group. The multivariate analysis identified a high uL-FABP level at baseline as a significant prognostic factor for poor OS (hazard ratio [HR]: 3.54, P = 0.002). The 5-year cumulative incidence rates for non-relapse mortality (NRM) were 50.0% in the high uL-FABP group and 19.9% in the low uL-FABP group. In the multivariate analysis, high uL-FABP at baseline was a significant prognostic factor for NRM (HR: 3.37, P = 0.01). uL-FABP levels did not significantly stratify the cumulative incidence of relapse (HR: 2.13, P = 0.11). uL-FABP levels on days 0, 7, and 14 were not significant survival predictors. High uL-FABP levels before the conditioning regimen significantly influence OS and NRM following SCT, whereas high uL-FABP levels at any point after the conditioning regimen do not. Our results show that measuring uL-FABP levels at baseline may be a simple way to predict survival in patients receiving SCT." @default.
• W4387424077 created "2023-10-08" @default.
• W4387424077 creator A5002104620 @default.
• W4387424077 creator A5005217874 @default.
• W4387424077 creator A5006703198 @default.
• W4387424077 creator A5008060903 @default.
• W4387424077 creator A5013877125 @default.
• W4387424077 creator A5015022898 @default.
• W4387424077 creator A5015029155 @default.
• W4387424077 creator A5016019785 @default.
• W4387424077 creator A5021720664 @default.
• W4387424077 creator A5027656839 @default.
• W4387424077 creator A5033486602 @default.
• W4387424077 creator A5041806547 @default.
• W4387424077 creator A5042854652 @default.
• W4387424077 creator A5047555337 @default.
• W4387424077 creator A5048935550 @default.
• W4387424077 creator A5051285783 @default.
• W4387424077 creator A5059165661 @default.
• W4387424077 creator A5059755849 @default.
• W4387424077 creator A5072500693 @default.
• W4387424077 creator A5072533536 @default.
• W4387424077 creator A5075476949 @default.
• W4387424077 creator A5087819309 @default.
• W4387424077 creator A5093021326 @default.
• W4387424077 creator A5093021327 @default.
• W4387424077 date "2023-10-01" @default.
• W4387424077 modified "2023-10-11" @default.
• W4387424077 title "Elevation of urinary liver-type fatty acid-binding protein is a harbinger of poor patient prognosis after allogeneic stem cell transplantation" @default.
• W4387424077 cites W1967300023 @default.
• W4387424077 cites W2034017748 @default.
• W4387424077 cites W2044583898 @default.
• W4387424077 cites W2049229230 @default.
• W4387424077 cites W2128812336 @default.
• W4387424077 cites W2157647997 @default.
• W4387424077 cites W2394983965 @default.
• W4387424077 cites W2414538242 @default.
• W4387424077 cites W2995161954 @default.
• W4387424077 cites W2999282126 @default.
• W4387424077 cites W3001829780 @default.
• W4387424077 cites W3004476155 @default.
• W4387424077 cites W3008914762 @default.
• W4387424077 cites W3166941653 @default.
• W4387424077 cites W3180224563 @default.
• W4387424077 cites W3201429400 @default.
• W4387424077 cites W4200198283 @default.
• W4387424077 cites W4283515860 @default.
• W4387424077 cites W4323659698 @default.
• W4387424077 doi "https://doi.org/10.1016/j.jtct.2023.10.003" @default.
• W4387424077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37813188" @default.
• W4387424077 hasPublicationYear "2023" @default.
• W4387424077 type Work @default.
• W4387424077 citedByCount "0" @default.
• W4387424077 crossrefType "journal-article" @default.
• W4387424077 hasAuthorship W4387424077A5002104620 @default.
• W4387424077 hasAuthorship W4387424077A5005217874 @default.
• W4387424077 hasAuthorship W4387424077A5006703198 @default.
• W4387424077 hasAuthorship W4387424077A5008060903 @default.
• W4387424077 hasAuthorship W4387424077A5013877125 @default.
• W4387424077 hasAuthorship W4387424077A5015022898 @default.
• W4387424077 hasAuthorship W4387424077A5015029155 @default.
• W4387424077 hasAuthorship W4387424077A5016019785 @default.
• W4387424077 hasAuthorship W4387424077A5021720664 @default.
• W4387424077 hasAuthorship W4387424077A5027656839 @default.
• W4387424077 hasAuthorship W4387424077A5033486602 @default.
• W4387424077 hasAuthorship W4387424077A5041806547 @default.
• W4387424077 hasAuthorship W4387424077A5042854652 @default.
• W4387424077 hasAuthorship W4387424077A5047555337 @default.
• W4387424077 hasAuthorship W4387424077A5048935550 @default.
• W4387424077 hasAuthorship W4387424077A5051285783 @default.
• W4387424077 hasAuthorship W4387424077A5059165661 @default.
• W4387424077 hasAuthorship W4387424077A5059755849 @default.
• W4387424077 hasAuthorship W4387424077A5072500693 @default.
• W4387424077 hasAuthorship W4387424077A5072533536 @default.
• W4387424077 hasAuthorship W4387424077A5075476949 @default.
• W4387424077 hasAuthorship W4387424077A5087819309 @default.
• W4387424077 hasAuthorship W4387424077A5093021326 @default.
• W4387424077 hasAuthorship W4387424077A5093021327 @default.
• W4387424077 hasConcept C126322002 @default.
• W4387424077 hasConcept C144301174 @default.
• W4387424077 hasConcept C188816634 @default.
• W4387424077 hasConcept C207103383 @default.
• W4387424077 hasConcept C2911091166 @default.
• W4387424077 hasConcept C38180746 @default.
• W4387424077 hasConcept C44249647 @default.
• W4387424077 hasConcept C50382708 @default.
• W4387424077 hasConcept C71924100 @default.
• W4387424077 hasConcept C77411442 @default.
• W4387424077 hasConcept C90924648 @default.
• W4387424077 hasConceptScore W4387424077C126322002 @default.
• W4387424077 hasConceptScore W4387424077C144301174 @default.
• W4387424077 hasConceptScore W4387424077C188816634 @default.
• W4387424077 hasConceptScore W4387424077C207103383 @default.
• W4387424077 hasConceptScore W4387424077C2911091166 @default.
• W4387424077 hasConceptScore W4387424077C38180746 @default.
• W4387424077 hasConceptScore W4387424077C44249647 @default.
• W4387424077 hasConceptScore W4387424077C50382708 @default.
• W4387424077 hasConceptScore W4387424077C71924100 @default.
• W4387424077 hasConceptScore W4387424077C77411442 @default.
• W4387424077 hasConceptScore W4387424077C90924648 @default.

• next